EPHA2 and breast carcinoma: Through clinical analysis, EphA2 was highly expressed in BLBC patients or triple-negative breast cancer (TNBC) patients based on DNA microarray data (Figure 1A-B, and Figure S1A) or TCGA data (Figure S1B), and its high expression indicated a poor prognosis in breast cancer patients (Figure S1C).